Company Overview and News


Add ADMA
to your dashboard

Headline News

Weekly Insider Trading

2017-12-28 seekingalpha
It is Christmas time and some extra time to... work! My pilot article ("Weekly Insider Trading") was published as recently as December 23, but it covered four biotech and IT companies with the most interesting insider trading dating back 3 months. This article follows my standard work and investing process by looking back at the last week’s most interesting transactions. (291-2)

Weekly Insider Trading

2017-12-23 seekingalpha
Radius Health: Well capitalized, has seen consistent insider activity from major owners as well as officers, and looks interesting from a technical chart perspective. (39-2)

Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center

2017-12-13 accesswire
LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On December 11, 2017, the Company, which is a vertically integrated commercial biopharmaceutical organization that develops, manufactures, and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Diseases, declared that it has filed a Biologics License Application (BLA) for its third plasma collection center. (6-1)

ADMA Biologics: Can We Trust This ~$3 Biotech Stock Again?

2017-11-27 seekingalpha
However, there has been some recent positive events for the company and a few insider purchases in the shares in early November. (5-2)

ADMA / ADMA Biologics Inc - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
ADMA Biologics Inc (NASDAQ:ADMA) has 20 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,749,036 shares. Largest shareholders include Biotest AG, Aisling Capital LLC, Biomark Capital Management Co. LLC, Consonance Capital Management LP, and Perceptive Advisors Llc. (5-2)

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

2017-10-11 reuters
* ADMA Biologics Inc - ‍entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management​ (5-0)

ADMA Biologics Follows Up On RI-002

2017-07-26 seekingalpha
ADMA Biologics acquired assets of Biotest Pharmaceuticals, including two FDA approved antibody products, manufacturing facility, and cash funding commitment. (0-2)

BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock

2017-06-16 reuters
* ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders Source text: (bit.ly/2twQ4Bo) Further company coverage: (0-1)

BRIEF-Seaworld Entertainment says David D'Alessandro did not receive majority of votes cast at annual meeting

2017-06-16 reuters
* Seaworld Entertainment Inc says David D'alessandro did not receive majority of votes cast at annual meeting - sec filing

BRIEF-Eagle Materials Inc says Laurence E. Hirsch, chairman, to retire from board

2017-06-16 reuters
* Eagle Materials Inc - on June 16, Laurence E. Hirsch, chairman, informed he has decided to retire from board

BRIEF-Biotest ‍sells US therapy business to Adma Biologics, Inc.​

2017-06-07 reuters
* ‍RECEIVES ALSO DISTRIBUTION RIGHTS OF SPECIFIED CURRENT PRODUCT AND A RIGHT OF FIRST OFFER FOR DISTRIBUTION OF FUTURE PRODUCTS OF ADMA FOR EUROPE, NEAR AND MIDDLE EAST AND SELECTED ASIAN COUNTRIES​ (0-1)

There's Never Been A Better Time To Buy ADMA Biologics

2017-04-07 seekingalpha
Recent acquisition of assets from Biotest Pharmaceuticals will decrease cost of screening and acquiring hyper donors.

Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of ADMA Biologics, Inc. - ADMA

2017-03-27 prnewswire
NEW YORK, March 27, 2017 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating  ADMA Biologics, Inc. ("ADMA" or the "Company")(NasdaqGS: ADMA)  and its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the Purchase Agreement with Biotest Pharmaceuticals Corporation for its therapy business (the "Purchase Agreement").

CUSIP: 000899104